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General.
All reagents commercially supplied were used as received. 1 H-and 13 C-NMR spectra were recorded on Bruker AMX-500 spectrometer. NMR spectra were recorded in (CD 3 ) 2 SO (99.9 atom % enriched, Kanto). 1 H chemical shifts were reported in δ value based on internal (CD 3 ) 2 SO (2.50 ppm) as a reference. 13 C chemical shifts were reported in δ value based on dimethyl sulfoxide (39.5 ppm) as a reference. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad), coupling constant (Hz), and integration. Mass spectra were obtained with a JEOL JMS-T100LP (ESI mode). Tandem MS analysis was conducted with a LTQ-Orbitrap XL (ThermoScientific).
Feeding experiments of 13 C-labeled methionine.
Seed cultures (3.0 mL) of S. lividans TK23 harboring pJawA or pJawB 1 were inoculated to 20 mL of Soytone medium {50 g of D-glucose, 20 g of Soytone, 0.3 g of KH 2 PO 4 , 0.4 g of K 2 HPO 4 and 0.2 g of MgSO 4 •7H 2 O per liter of water (pH 7.0)} containing thiostrepton (10 μg/mL) in 100 mL baffled shake flask and grown at 30°C for 2 days with agitation. The culture broth (0.3 mL) was further inoculated to 5.7 mL of Soytone broth containing thiostrepton (10 μg/ml) in 100 mL baffled shake flask. To this culture was added L-[Me-13 C 1 ]methionine (final concentration: 1 mg/mL). Cultivation was continued for an additional 3 days at 30°C. The culture broth was extracted with ethyl acetate and the organic layers were evaporated to dryness under reduced pressure. The crude mixture was dissolved in 300 μL of acetonitrile and the sample solution (10 L) was directly analysed by LC-MS/MS with InertSustain C18 (1.0 mm x 10 mm, GL science) using a linear gradient from 20% to 38% Solution B for 0-5 min, 38% to 45% for 5-30 min, 45% to 60% for 30-35 min, 60% to 100% for 35-36 min, 100% Solution B additional 9 min. Solution A: 98% of water and 2% of acetonitrile containing 0.1% formic acid, Solution B: 10% of water and 90% acetonitrile containing 0.1% formic acid.
Isolation of jawsamycin analogs.
S. lividans TK23 harboring pJawA or pJawB was grown on Soytone medium (100 mL) containing thiostrepton (20 μg/mL) in baffled shake flask (500 mL). Fermentation was carried out for 1 week at 30°C with agitation. The culture broth (2.4 L) was extracted with ethyl acetate. The organic layers were evaporated to dryness under reduced pressure. The resultant was dissolved in a small volume of DMSO and purified by preparative HPLC. The crude extracts were separated by HPLC with Wakopack Navi C18-5 (10 mm x 250 mm, Wako) [column temperature, 30°C; flow rate, 2.5 mL/min] using a linear gradient from 70% to 74% acetonitrile for 0-14 min, 74% to 95% for 14-15 min, 95% acetonitrile additional 1 min, 95% to 70% for 16-16.5 min, and 70% acetonitrile for an additional 8.5 min. The crude fraction was further separated by the following HPLC conditions to give the following analogs;
3 (C 16 -CP 5 ): The crude fraction containing 3 was purified by HPLC with Wakopack Navi C18-5 (10 mm x 250 mm, Wako) [column temperature, 30°C; flow rate, 2.5 mL/min] using a linear gradient from 55% to 55% acetonitrile for 0-17 min, 55% to 90% for 17-18 min, 95% to 55% for 18-18.5 min, and 55% acetonitrile for an additional 8.5 min to yield 3 (1.8 mg).
[] D 20 -98.1 (c 0.094 (CH 3 ) 2 SO). ESI-HR-MS (positive) calculated for C 30 H 40 N 3 O 6 [M+H] + 538.2912, found m/z 538.2936. NMR data of 3 are summarized in Table S3 . 4 (C 16 -CP 4 ): The crude fraction containing 4 was purified by HPLC with Wakopack Navi C18-5 (10 mm x 250 mm, Wako) [column temperature, 30°C; flow rate, 2.5 mL/min] using a linear gradient from 65% to 65% acetonitrile for 0-14 min, 65% to 95% for 14-15 min, 95% acetonitrile additional 1 min, 95% to 65% for 16-16.5 min, and 65% acetonitrile for an additional 8.5 min to yield 4 (2.6 mg).
[] D 20 -211.3 (c 0.46 (CH 3 ) 2 SO). ESI-HR-MS (positive) calculated for C 29 H 38 N 3 O 6 [M+H] + 524.2755, found m/z 524.2727. NMR data of 4 are summarized in Table S3 .
2a (C 18 -CP 4 ): The crude fraction containing 2a was purified by HPLC with Wakopack Navi C18-5 (10 mm x 250 mm, Wako) [column temperature, 30°C; flow rate, 2.5 mL/min] using a linear gradient from 72% to 72% acetonitrile for 0-14 min, 72% to 95% for 14-15 min, 95% acetonitrile additional 1 min, 95% to 72% for 16-16.5 min, and 72% acetonitrile for an additional 8.5 min to yield 2a (1.0 mg).
[] D 20 -60.4 (c 0.087 (CH 3 ) 2 SO). ESI-HR-MS (positive) calculated for C 31 Table S3 . Table S3 .
4a (C 16 -CP 3 ): The crude fraction containing 4a was purified by HPLC with Wakopack Navi C18-5 (10 mm x 250 mm, Wako) [column temperature, 30°C; flow rate, 2.5 mL/min] using a linear gradient from 60% to 60% acetonitrile for 0-14 min, 60% to 95% for 14-15 min, 95% acetonitrile additional 1 min, 95% to 60% for 16-16.5 min, and 60% acetonitrile for an additional 8.5 min to yield 4a (1.6 mg) as a mixture of isomers (4a/isomer = 5/1 ratio).
[] D 20 -39.7 (c 0.10 (CH 3 ) 2 SO). ESI-HR-MS (positive) calculated for C 28 H 36 N 3 O 6 [M+H] + 510.2599, found m/z 510.2590. NMR data of 4a are summarized in Table S3 . Figure S3 . LC-HRMS and MS/MS analysis of (A) 13 C-labeled 2, (B) 13 C-labeled C 18 -CP 4 analogs, and (C) 13 C-labeled C 18 -CP 3 analogs, which were obtained from the feeding experiment with L-[Me-13 C]methionine. In this feeding experiment shown in Figure S3 -S8, a major isotopomer was found to be a fully 13 C-enriched sample (~50%) at a methylene carbon of the cyclopropane moiety. The carbon-13 labels are shown in the gray circles. An increased mass number of each fragmentation compared with that of non-labeled one is shown in parenthesis. (D) Summary of high resolution mass spectrometry of each compound. Figure S4 . LC-HRMS and MS/MS analysis of (A) 13 C-labeled 3, (B) 13 C-labeled 4 and 3a, (C) 13 Clabeled C 16 -CP 3 analogs, and (D) 13 C-labeled C 16 -CP 2 analog, which were obtained from the feeding experiment with L-[Me-13 C]methionine. The carbon-13 labels are shown in the gray circles. An increased mass number of each fragmentation compared with that of non-labeled one is shown in parenthesis. (E) Summary of high resolution mass spectrometry of each compound. Figure S5 . LC-HRMS and MS/MS analysis of (A) 13 C-labeled C 14 -CP 5 analog, (B) 13 C-labeled C 14 -CP 4 analog, (C) 13 C-labeled C 14 -CP 3 analogs, (D) 13 C-labeled C 14 -CP 2 analogs, and (E) 13 C-labeled C 14 -CP 1 analog, which are obtained from the feeding experiment with L-[Me-13 C]methionine. An increased mass number of each fragmentation compared with that of non-labeled one is shown in parenthesis. (F) Summary of high resolution mass spectrometry of each compound. Figure S6 . LC-HRMS and MS/MS analysis of (A) 13 C-labeled C 12 -CP 4 analog, (B) 13 C-labeled C 12 -CP 3 analog, (C) 13 C-labeled C 12 -CP 2 analog, and (D) 13 C-labeled C 12 -CP 1 analogs, which are obtained from the feeding experiment with L-[Me-13 C]methionine. An increased mass number of each fragmentation compared with that of non-labeled one is shown in parenthesis. (E) Summary of high resolution mass spectrometry of each compound. Figure S7 . LC-HRMS and MS/MS analysis of (A) 13 C-labeled C 10 -CP 1 analog, which are obtained from the feeding experiment with L-[Me-13 C]methionine. An increased mass number of each fragmentation compared with that of non-labeled one is shown in parenthesis. (B) Summary of high resolution mass spectrometry of each compound. Figure S8 . LC-HRMS and MS/MS analysis of (A) 13 C-labeled C 8 -CP 1 analog and (B) 13 C-labeled C 8 -CP 0 analog, which are obtained from the feeding experiment with L-[Me-13 C]methionine. An increased mass number of each fragmentation compared with that of non-labeled one is shown in parenthesis. (C) Summary of high resolution mass spectrometry of each compound. Figure S9 . LC-HRMS and MS/MS analysis of (A) 13 C-labeled 1, (B) 13 C-labeled C 18 -CP 4 analogs, and (C) 13 C-labeled C 18 -CP 3 analog, which are obtained from the feeding experiment with L-[Me-13 C]methionine. In this feeding experiment shown in Figure S9 -S13, a major isotopomer was found to be a fully 13 C-enriched sample (~50%) at a methylene carbon of the cyclopropane moiety. The carbon-13 labels are shown in the gray circles. An increased mass number of each fragmentation compared with that of non-labeled one is shown in parenthesis. (D) Summary of high resolution mass spectrometry of each compound. Figure S10 . LC-HRMS and MS/MS analysis of (A) 13 C-labeled C 16 -CP 5 analog, (B) 13 C-labeled C 16 -CP 4 analogs, (C) 13 C-labeled C 16 -CP 3 analogs, and (D) 13 C-labeled C 16 -CP 2 analog, which are obtained from the feeding experiment with L-[Me-13 C]methionine. An increased mass number of each fragmentation compared with that of non-labeled one is shown in parenthesis. (E) Summary of high resolution mass spectrometry of each compound. Figure S11 . LC-HRMS and MS/MS analysis of (A) 13 C-labeled C 14 -CP 5 analog, (B) 13 C-labeled C 14 -CP 4 analog, (C) 13 C-labeled C 14 -CP 3 analogs, (D) 13 C-labeled C 14 -CP 2 analogs, and (E) 13 C-labeled C 14 -CP 1 analog, which are obtained from the feeding experiment with L-[Me-13 C]methionine. An increased mass number of each fragmentation compared with that of non-labeled one is shown in parenthesis. (F) Summary of high resolution mass spectrometry of each compound. Figure S12 . LC-HRMS and MS/MS analysis of (A) 13 C-labeled C 12 -CP 4 analog, (B) 13 C-labeled C 12 -CP 3 analog, (C) 13 C-labeled C 12 -CP 2 analog, and (D) 13 C-labeled C 11 -CP 1 analogs, which are obtained from the feeding experiment with L-[Me-13 C]methionine. An increased mass number of each fragmentation compared with that of non-labeled one is shown in parenthesis. (E) Summary of high resolution mass spectrometry of each compound. Figure S13 . LC-HRMS and MS/MS analysis of (A) 13 C-labeled C 8 -CP 1 analog, which are obtained from the feeding experiment with L-[Me-13 C]methionine. An increased mass number of each fragmentation compared with that of non-labeled one is shown in parenthesis. (B) Summary of high resolution mass spectrometry of each compound. Figure S14 . MS analysis of crude metabolites from jawsamycin producing S. fervens HP-891. Scheme S1. Proposed biosynthetic pathway for 2a-4a harboring terminal conjugated diene. The isolated analogs are labeled with asterisks. Numbering of the double bond is shown on upper part of the polyketide structure. S1. Number of polyketide isomers of (A) 2 analogs and (B) 1 analogs. Compounds, which were not observed in the LC-HR-MS/MS analysis, are shown in horizontal bars (-). C 10 -CP 5 , C 8 -CP 5 , and C 8 -CP 4 are not biosynthetically available and the corresponding columns are shown in grey color. 
